Search Result

Results for "

metastatic prostate cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PSMA (5) ADC Linker (2) Androgen Receptor (4) Apoptosis (5) Autophagy (2) Cathepsin (1) CD3 (1) CTLA-4 (1) Cytochrome P450 (2) Dengue Virus (1) DNA-PK (2) Drug Metabolite (2) Epigenetic Reader Domain (1) Flavivirus (1) Glycosidase (1) Heme Oxygenase (HO) (1) Histone Methyltransferase (2) HPV (1) IAP (2) Microtubule/Tubulin (1) NF-κB (2) PD-1/PD-L1 (1) PROTACs (2) Radionuclide-Drug Conjugates (RDCs) (1) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Ser/Thr Protease (1) Survivin (1) VSV (1) Wnt (2)
By Research Areas:	Cancer (34) Inflammation/Immunology (4)

By Targets:

PSMA (5)

ADC Linker (2)

Androgen Receptor (4)

Apoptosis (5)

Autophagy (2)

Cathepsin (1)

CD3 (1)

CTLA-4 (1)

Cytochrome P450 (2)

Dengue Virus (1)

DNA-PK (2)

Drug Metabolite (2)

Epigenetic Reader Domain (1)

Flavivirus (1)

Glycosidase (1)

Heme Oxygenase (HO) (1)

Histone Methyltransferase (2)

HPV (1)

IAP (2)

Microtubule/Tubulin (1)

NF-κB (2)

PD-1/PD-L1 (1)

PROTACs (2)

Radionuclide-Drug Conjugates (RDCs) (1)

Ras (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

Ser/Thr Protease (1)

Survivin (1)

VSV (1)

Wnt (2)

By Research Areas:

Cancer (34)

Inflammation/Immunology (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: PSMA BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156628

Opevesostat MK-5684; ODM-208	Cytochrome P450	Cancer
Opevesostat (MK-5684; ODM-208) is an orally active and selective CYP11A1 inhibitor. Opevesostat has the potential for the research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-158102

ORIC-944	Histone Methyltransferase	Cancer
ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.

HY-158102A

ORIC-944 TFA	Histone Methyltransferase	Cancer
ORIC-944 TFA is the TFA salt form of ORIC (HY-158102). ORIC-944 TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer .

HY-158125

PSMA binder-2	PSMA	Cancer
PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-158118

Lys(CO-C3-p-I-Ph)-OMe	DNA-PK	Cancer
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P9992

Pelgifatamab BAY-2315497; PSMA-TTC	PSMA	Inflammation/Immunology
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of ²²⁵Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .

HY-128938A

EC1167 hydrochloride	ADC Linker	Cancer
EC1167 hydrochloride is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 hydrochloride has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC) .

HY-19833

CFG920	Cytochrome P450	Cancer
CFG920 is an orally active, nonsteroidal, reversible dual CYP17 and CYP11B2 inhibitor. CFG920 has the potential for metastatic castration-resistant prostate cancer research .

HY-119001

BKM1644	Survivin	Cancer
BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .

HY-128938

EC1167	ADC Linker	Cancer
EC1167 is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC) .

HY-118134

Hepln-13	Ser/Thr Protease	Cancer
Hepln-13 is a potent and orally active Hepsin inhibitor with an IC₅₀ of 0.33 μM. Hepln-13 can be used for the research of metastatic prostate cancer .

HY-152520

RLA-5331	Androgen Receptor	Cancer
RLA-5331 is an iron activator containing anti-androgen. RLA-5331 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line .

HY-152512

RLA-4842	Androgen Receptor	Cancer
RLA-4842 is an iron activator containing anti-androgen. RLA-4842 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line .

HY-103385

NCX4040 NO-Aspirin	Apoptosis	Inflammation/Immunology Cancer
NCX4040 (NO-Aspirin), a non-steroidal anti-inflammatory drug (NSAID), is a nitric oxide (NO) releasing form of Aspirin. NCX4040 induces apoptosis in PC3 metastatic prostate cancer cells. NCX4040 has anti-inflammatory and anti-cancer effects .

HY-120599

Sabizabulin 2 Publications Verification VERU-111; ABI-231	Microtubule/Tubulin Apoptosis HPV	Cancer
VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC₅₀ of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer .

HY-146397

TD-802	PROTACs Androgen Receptor	Cancer
TD-802 (Compound 33c) is an androgen receptor (AR) PROTAC degrader with good microsomal stability. TD-802 has good antitumor efficacy in vivo and can be used for metastatic castration-resistant prostate cancer research .

HY-109050

Alobresib 2 Publications Verification GS-5829	Epigenetic Reader Domain	Cancer
Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research .

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212; MT112	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-103385R

NCX4040 (Standard) NO-Aspirin (Standard)	Reference Standards Apoptosis	Inflammation/Immunology Cancer
NCX4040 (Standard) is the analytical standard of NCX4040. This product is intended for research and analytical applications. NCX4040 (NO-Aspirin), a non-steroidal anti-inflammatory drug (NSAID), is a nitric oxide (NO) releasing form of Aspirin. NCX4040 induces apoptosis in PC3 metastatic prostate cancer cells. NCX4040 has anti-inflammatory and anti-cancer effects .

HY-138641

Bavdegalutamide 4 Publications Verification ARV-110	PROTACs Androgen Receptor	Cancer
Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer (Pink: AR ligand (HY-168299); Blue: E3 ligase ligand (HY-W093272); Black: linker (HY-W091986)) .

HY-N2022

Castanospermine 2 Publications Verification	Glycosidase	Inflammation/Immunology Cancer
Castanospermine is a natural alkaloid that can be extracted from black beans or the Moreton Bay chestnut tree (Castanospermum australae). Castanospermine is an α/ β-glucosidase inhibitor. Castanospermine has anti-inflammatory, antiviral replication and anti-metastatic effects on prostate cancer. Castanospermine can be used as an immunosuppressant to prevent transplant rejection .

HY-P1416

Foxy-5 Maximum Cited Publications 6 Publications Verification	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-118487

OB-24 1 Publications Verification	Heme Oxygenase (HO) Reactive Oxygen Species (ROS)	Cancer
OB-24 is a selective small-molecule HO-1 inhibitor (IC₅₀ = 1.9 μM for HO-1 and IC₅₀ for HO-2 >100 μM). OB-24 possesses anti-tumor and anti-metastatic properties. OB-24 can be studies in research such as prostate cancer, melanoma, ovarian carcinoma and lung metastasis_[1]_[2].

HY-P1416A

Foxy-5 TFA Maximum Cited Publications 6 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-70002BR

Enzalutamide carboxylic acid (Standard)	Drug Metabolite	Cancer
Bromoxynil octanoate (Standard) is the analytical standard of Bromoxynil octanoate. This product is intended for research and analytical applications. Bromoxynil octanoate is an herbicide widely applied to maize, is potentially toxic to both animals and humans .

HY-70002B

Enzalutamide carboxylic acid 1 Publications Verification MDV3100 carboxylic acid	Drug Metabolite	Cancer
Enzalutamide carboxylic acid (MDV3100 carboxylic acid) is an inactive metabolite of Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist .

HY-17473

Embelin 4 Publications Verification Embelic acid; Emberine; NSC 91874	IAP NF-κB Apoptosis Autophagy	Cancer
Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC₅₀=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .

HY-158119A

PSMA-trillium	PSMA	Cancer
PSMA-trillium is a PSMA targeting compound, consisting of a PSMA targeting molecule (PSMA binder), a Macropa chelating molecule, and a group that regulates pharmacokinetics (PK modifier). PSMA-trillium is a non-radioactive form of Actinium-225-PSMA-Trillium (BAY 3563254) with improved PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind Ac through the Macropa chelating molecule, or the radioactive isotope ²²⁵Actinium. Actinium-225-PSMA-Trillium is a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC) .

HY-17473R

Embelin (Standard)	IAP NF-κB Apoptosis Autophagy	Cancer
Embelin (Standard) is the analytical standard of Embelin. This product is intended for research and analytical applications. Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC50=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .

HY-158123

PSMA binder-1	PSMA	Cancer
PSMA binder-1 is a ligand for PSMA and can be used to synthesize PSMA targeting molecule, such as Ac-PSMA-trillium .

HY-158122

Lys(CO-C3-p-I-Ph)-O-tBu	DNA-PK	Cancer
Lys(CO-C3-p-I-Ph)-O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the pharmacokinetic properties of PSMA ligand molecules. Lys(CO-C3-p-I-Ph)-O-tBu can increase the residence time of PSMA ligand in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-O-tBu also reduces salivary gland absorption, possibly extending the half-life of the active compound .

HY-13963

ZCL278 2 Publications Verification	Flavivirus Dengue Virus VSV Ras	Cancer
ZCL278 is a selective Cdc42 modulator that directly binds to Cdc42 and inhibits its functions with K_d of 11.4 μM for Cdc42-ZCL278 affinity in surface plasmon resonance (SPR) experiment.

HY-118762

KGP94	Cathepsin	Cancer
KGP94 is a selective inhibitor of cathepsin L with an IC₅₀ of 189 nM . KGP94 inhibits migration and invasion of metastatic carcinoma and shows low cytotoxicity (GI₅₀=26.9 µM) against various human cell lines .

Cat. No.	Product Name	Target	Research Area